This website sells research peptides exclusively for scientific and laboratory research purposes.
Do you confirm you are 18+ and accessing this site for legitimate research purposes?
RAD-140 and LGD-4033 are both nonsteroidal selective androgen receptor modulators with high binding affinity, but their research profiles reveal important differences. RAD-140 research has explored potential neuroprotective properties through androgen receptor activation in brain tissue — a research application not associated with LGD-4033. LGD-4033 research has focused primarily on anabolic effects in muscle and bone tissue with high selectivity over other androgen-sensitive tissues. Pharmacokinetic research shows RAD-140 has a longer half-life of approximately 60 hours compared to LGD-4033 at approximately 24–36 hours. Both compounds have been subjects of published clinical pharmacokinetic studies, with dose-escalation data available in the research literature. Binding affinity studies suggest RAD-140 may have higher androgen receptor binding affinity than LGD-4033, though direct head-to-head binding studies are limited. Tissue selectivity profiles differ, with each compound showing distinct ratios of anabolic to androgenic activity in research models.
